Cochlear Limited is a global medical device company specializing in implantable hearing solutions for individuals with severe to profound hearing loss. The company’s core business revolves around the design, manufacture and distribution of cochlear implant systems, bone conduction hearing implants and acoustic implantable devices. These products are complemented by an ecosystem of accessories, software and support services that enable hearing care professionals to fit, program and monitor patient outcomes.
Cochlear’s flagship offerings include the Nucleus® cochlear implant system, which converts sound into electrical impulses delivered directly to the auditory nerve, and the Baha® bone conduction system, which transmits sound through bone vibration for patients with conductive hearing loss or single-sided deafness. The company also develops Remote Check, a digital follow-up tool that allows patients to complete hearing assessments and device adjustments remotely, enhancing access to care.
Founded in 1981 by Professor Graeme Clark at the University of Melbourne, Cochlear achieved its first commercial cochlear implant launch in 1982. Headquartered in Sydney, Australia, the company now operates manufacturing and research facilities in Australia, the United States and Europe, and distributes its products in over 100 countries. Cochlear’s global footprint is supported by a network of subsidiaries, distributors and clinical partners that provide training, rehabilitation services and technical support.
Under the leadership of CEO David Hunt, appointed in early 2020, Cochlear continues to invest in research and development to advance hearing implant technologies, pursue new market opportunities and improve patient outcomes. The company’s multidisciplinary teams collaborate with surgeons, audiologists and academic institutions worldwide to drive innovation in hearing restoration.
AI Generated. May Contain Errors.
